Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLQOF1)

• Drug Name: MK-7246 Drug Info
• Synonyms: IDDBCP261213; IDDBCP271467

Indication

Disease Entry	ICD 11	Status	REF
Respiratory disease	CB40	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 45268455
  CAS Number: CAS 1218918-62-7
  TTD Drug ID: DMLQOF1
  VARIDT Drug ID: DR00751
  INTEDE Drug ID: DR1806

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin D2 receptor 2 (PTGDR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[4]
Setipiprant	DMZ61IA	Asthma	CA23	Phase 3	[5]
Fevipiprant	DM4NX0C	Asthma	CA23	Phase 3	[6]
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[7]
AMG 853	DM973N4	Asthma	CA23	Phase 2	[8]
ADC-3680	DM8GHIX	Allergic rhinitis	CA08.0	Phase 2	[9]
ARRY-502	DM17469	Allergic asthma	CA23.0	Phase 2	[10]
QAV-680	DMIZYV1	Allergic rhinitis	CA08.0	Phase 2	[11]
AP-761	DMISQOZ	Asthma	CA23	Phase 2	[12]
AZD1981	DMMCL9F	Chronic obstructive pulmonary disease	CA22	Phase 2	[13]

Drug(s) Metabolized By UDP-glucuronosyltransferase 2B17 (UGT2B17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[14]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[15]
Denopamine	DM8C3GN	Cardiac disease	BA00-BE2Z	Approved	[16]
Hydroxybenzo[a]pyrene	DMFSKYE	N. A.	N. A.	Investigative	[17]
Hydroxybenzo(a)pyrene	DM9H5EN	N. A.	N. A.	Investigative	[17]
BRN-1980310	DMOTU4P	N. A.	N. A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin D2 receptor 2 (PTGDR2)	TTQDMX5	PD2R2_HUMAN	Modulator	[2]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 2B17 (UGT2B17) Main DME	DEAZDL8	UDB17_HUMAN	Substrate	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031315)
• [2] Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93.
• [3] UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study. Clin Pharmacol Ther. 2012 Jul;92(1):96-102.
• [4] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [5] Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
• [6] Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207.
• [7] CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7.
• [8] Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
• [9] Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
• [10] Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502).
• [11] Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464)
• [13] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [14] Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016 Nov 16;7:437.
• [15] Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
• [16] Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Drug Metab Dispos. 2005 Mar;33(3):403-12.
• [17] Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos. 2006 Jun;34(6):943-9.